Asymptomatic Rhabdomyolysis in a Young Adult With COVID-19

Abdelhadi Farouji, Rabea Hellou, Asaf Peretz

1. Internal Medicine, Assuta Ashdod Medical Center, Ben-Gurion University of the Negev, Ashdod, ISR

Corresponding author: Abdelhadi Farouji, abdfarroujeh@hotmail.com

Abstract
The novel coronavirus disease 2019 (COVID-19) is an ongoing pandemic. Although COVID-19 is frequently associated with respiratory symptoms and complications, multiple extrapulmonary manifestations have been identified since the beginning of the pandemic. Rhabdomyolysis has been described in the literature as one of the extrapulmonary manifestations of COVID-19. Herein, we describe a 21-year-old male patient who presented with cough and fever secondary to COVID-19 confirmed by positive reverse-transcription polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The patient presented with an extremely elevated creatinine kinase (CK) of 53,886 U/L (normal 10-170) without any classical symptoms of rhabdomyolysis or deterioration in his kidney function. He was successfully managed with aggressive intravenous fluids. The aim of reporting this case is to highlight the importance of including total CK in the initial evaluation of COVID-19 patients.

Categories: Internal Medicine, Infectious Disease
Keywords: elevated ck levels, covid 19, rhabdomyolysis, atypical presentation, young adult male

Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged in China in December 2019 and shortly thereafter has spread worldwide. According to the Johns Hopkins Coronavirus Resource Center, as of July 24, 2021, more than 193 million patients and 4.1 million deaths have been reported worldwide [1]. The disease may present with different symptoms including cough, fever, myalgia, headache, dyspnea, sore throat, diarrhea, loss of smell or taste, and others [2]. Although respiratory symptoms predominate, different extrapulmonary manifestations have been reported, such as myocardial infarction, myocarditis, pericarditis, pulmonary embolism, stroke, encephalitis, Guillain-Barre syndrome, and rhabdomyolysis [3]. Herein, we describe a young adult patient who developed coronavirus disease 2019 (COVID-19)-associated rhabdomyolysis without its classical symptoms and signs like myalgia, weakness, or dark urine.

Case Presentation
A 21-year-old patient, with no significant past medical history presented to the outpatient clinic with fever and cough and was diagnosed with COVID-19, confirmed by RT-PCR test. Seven days later, he presented to the emergency room with complaints of fever, cough, and shortness of breath. He denied weakness, myalgia, or any change in the color of his urine. His initial vitals upon arrival revealed a respiratory rate of 18 breaths/minute, heart rate of 95 beats/minute, blood pressure 119/77 mmHg, with a temperature of 39.2 degrees Celsius. The patient was not hypoxic at presentation with oxygen saturation of 98% on room air. His physical examination was unremarkable.

His initial complete blood count and metabolic panel were within normal limits. He had total creatinine kinase (CK) of 53,886 units/L (normal 10-170) at presentation to the ER (seven days after diagnosis with COVID-19), creatinine 0.8 mg/dL (normal 0.7-1.2), C-reactive protein (CRP) 35.3 mg/L (normal < 5.00), ferritin 314 ng/mL (normal 30-400), aspartate aminotransferase (AST) 653 units/L (normal 5-40), and alanine aminotransferase (ALT) 182 units/L (normal 4-41). The urine drug screen was negative. Urinalysis and urine myoglobin were not tested. Chest x-ray (CXR) showed patchy infiltrates in the right lower hemithorax (Figure 1).
The patient was admitted to the COVID-19 designated department because of rhabdomyolysis. We excluded other possible causes of rhabdomyolysis; he denied excessive exercise or strenuous activity a few days prior to his admission, no evidence of trauma on physical examination, urine drug screen was negative, ethanol level was undetectable, no past medication history except acetaminophen for fever, nasopharyngeal RT-PCR for the respiratory syncytial virus, influenza A and B were negative, and serology for HIV, hepatitis B and C were negative. This suggests that his rhabdomyolysis was most likely due to COVID-19. During his hospitalization, he received aggressive treatment with an intravenous infusion of normal saline (NaCl 0.9%) at a rate of 200 mL/h. CK levels decreased to 6920 U/L on day four of therapy, following which he was discharged. Twelve days after discharge, blood tests were done at an outpatient clinic and showed a decrease in the CK levels down to 209 U/L. The CK and creatinine levels are shown in the graphs (Figures 2, 3).

FIGURE 1: Chest X-ray showing right lobe infiltrates (circle).

FIGURE 2: Graph showing trends of CK levels.

CK: creatinine kinase
FIGURE 3: Graph showing trends of creatinine levels.

Discussion

Rhabdomyolysis is a potentially life-threatening syndrome characterized by the breakdown of skeletal muscle resulting in the subsequent release of intracellular contents into the circulatory system. These cell contents include enzymes such as CK, glutamic oxaloacetic transaminase, lactate dehydrogenase, aldolase, myoglobin, electrolytes such as potassium and phosphates, and purines. The characteristic complaints in rhabdomyolysis are muscle pain, weakness, and dark urine. However, more than half of the patients may not report muscular symptoms, as was with our patient.

Rhabdomyolysis is diagnosed by the elevation in serum CK, and while there is no established serum level cut-off, many clinicians use five times the upper limit of normal (approximately 1000 U/L). Our patient had extremely elevated CK up to 53,886 U/L at the time of admission confirming the diagnosis.

Rhabdomyolysis can cause a wide range of complications because of the release of these intracellular contents. One of these complications is acute kidney injury with a reported frequency between 33% and 51%, renal injury can develop when the myoglobin release exceeds the serum protein-binding capacity and the excess pigment precipitates in glomeruli. Other complications include hyperkalemia, metabolic acidosis, disseminated intravascular coagulation, compartment syndrome, arrhythmias, and cardiac arrest.

Many conditions may lead to rhabdomyolysis, not limited to alcohol and drug abuse, medications, trauma, epileptic seizures, excessive exercise, prolonged immobilization, metabolic disturbance, local or generalized muscle ischemia, and heat stroke. Besides that, many bacterial, viral, fungal, and parasitic infections have been described in the literature as causes of rhabdomyolysis. Viruses that have been reported to cause rhabdomyolysis are influenza, parainfluenza, coxsackievirus, Epstein–Barr virus, cytomegalovirus, herpes simplex virus, human immunodeficiency virus, adenovirus, echovirus, and hepatitis B and C. Influenza virus is the most common cause of viral-induced rhabdomyolysis accounting for approximately 33% of known cases.

Since the outbreak of the COVID-19 pandemic, multiple case reports have described COVID-19 associated rhabdomyolysis. Some of these cases described rhabdomyolysis as a potential late complication associated with COVID-19. Rhabdomyolysis was reported with the initial presentation of COVID-19 infection by others. Our case reports a young adult patient that presented with a cough and fever. The unique aspect of our case was the lack of classical symptoms of rhabdomyolysis such as myalgia, weakness, and dark urine with an extremely elevated level of CK up to 53,886 U/L. This suggests COVID-19 to be the likely etiology as the other causes have been ruled out. There are cases that reported COVID-19 associated rhabdomyolysis in pediatric and young adults (18-35 years) (Table 1).
| Author characteristic | Our case | Meegada et al. [20] | Gefen et al. [21] | Tram et al. [22] | McCarthy [23] | Anwar and Al Lawati [24] | Samies et al. [25] |
|------------------------|----------|---------------------|------------------|----------------|-------------|--------------------------|-------------------|
| Age (years)            | 21       | 19                  | 16               | 15             | 34          | 16                       | 16                |
| Sex                    | M        | M                   | M                | M              | M           | M                        | M                 |
| Medical history        | Healthy  | Ulcerative colitis  | ADHD, OSA, autism spectrum disorder, morbid obesity, and eczema | Healthy | Prediabetes and obesity | Healthy | Obesity, type 2 diabetes mellitus, OSA, HTN |
| Trauma or physical exercise | No      | No                  | No               | No             | Not mentioned | Yes                      | No                |
| Previous rhabdomyolysis | No      | No                  | No               | No             | No          | Yes                      | No                |
| Presentation           | Cough, fever, and fatigue | Abdominal pain | Myalgia, fatigue, SOB, and cola-colored urine | Proximal muscle pain, tea-colored urine, polyuria, polydipsia, and general fatigue | Fever, cough, SOB, and fever | Fever, sore throat, myalgia, and SOB | Fever, dark-colored urine, myalgia, sore throat, cough |
| CK on presentation (U/L) | 53,886  | 22,000              | 427,656          | 21,876         | 623         | Not mentioned            | 274,664           |
| Peak CK (U/L)          | 53,886  | 22,000              | 427,656          | 21,876         | 5454        | Not mentioned            | >426,700          |
| Creatinine (mg/dL)     | 0.9      | 1.28                | 0.89             | 8.91           | 0.89        | Not mentioned            | 12.03             |
| Treatment              | IV fluids | IV fluids | IV fluids and bicarb | IV fluids and bicarb | Not mentioned | Not mentioned | IV fluids, diuretics, and hemodialysis |
| Outcome                | Discharged alive | Discharged alive | Discharged alive | Discharged alive | Died         | Died                      | Discharged alive  |

**TABLE 1:** Clinical characteristics of patients (pediatrics and young adults 18-35 years) with COVID-19 associated rhabdomyolysis.

M: male; F: female; ADHD: attention-deficit/hyperactivity disorder; OSA: obstructive sleep apnea; HTN: hypertension; SOB: shortness of breath; CK: creatine kinase; COVID-19: coronavirus disease 2019

The mechanism by which COVID-19 causes muscle damage is uncertain, but various mechanisms have been described for another viral myositis, including direct invasion of muscle tissue by the virus [9,13], immunologic processes induced by the virus that results in muscle damage, and the cytokine storm released in response to viral infection [9,26]. Many cases were reported during the outbreak of SARS, which supports the theory of the cytokine storm theory as the mechanism of the rhabdomyolysis which has been confirmed by the presence of elevated inflammatory markers found in muscle biopsies of patients infected with the virus [27,28].

The treatment of rhabdomyolysis includes aggressive fluid administration, addressing the underlying cause, and management of electrolyte abnormalities in order to prevent acute kidney injury and severe metabolic disturbances [4]. Our patient responded well to the aggressive intravenous fluids; his creatinine level was normal throughout his hospital stay and his CK levels steadily declined. He didn’t develop acute kidney injury or any complications during the course of his disease.

**Conclusions**

In conclusion, we are reporting a case of COVID-19-associated rhabdomyolysis in a young adult male patient that developed significant rhabdomyolysis without classical symptoms. Our case aims to highlight the importance of including total CK in the initial evaluation of COVID-19 patients in order to prevent any
further complications including acute kidney injury and electrolyte abnormalities.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). (2021). Accessed: July 24, 2021: https://coronavirus.jhu.edu/map.html.
2. Stokes EK, Zambrano LD, Andersen RN, et al.: Coronavirus disease 2019 case surveillance - United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020, 69:759-65. 10.15585/mmwr.mm6924e2
3. Ahbaker A, Raba AA, Alzwi A: Extrapulmonary and atypical clinical presentations of COVID-19. J Med Virol. 2020, 92:2458-64. 10.1002/jmv.25617
4. Khan FY: Rhabdomyolysis: a review of the literature. Neth J Med. 2009, 67:272-83.
5. Gabow PA, Kaehny WD, Kelleher SP: The spectrum of rhabdomyolysis. Medicine (Baltimore). 1982, 61:141-52. 10.1097/00005850-198205000-00002
6. Bagley WH, Yang H, Shah KH: Rhabdomyolysis. Intern Emerg Med. 2007, 2:210-8. 10.1007/a11739-007-0060-8
7. Veenstra J, Smit WM, Krediet RT, Arisz L: Relationship between elevated creatine phosphokinase and the clinical spectrum of rhabdomyolysis. Nephrol Dial Transplant. 1994, 9:637-41. 10.1093/ndt/9.6.637
8. Zutt R, van der Kooi AJ, Linthorst GE, Wanders RJ, de Visser M: Rhabdomyolysis: review of the literature. Neuromusc Disord. 2014, 24:651-9. 10.1016/j.nmd.2014.05.005
9. Singh U, Scheld WM: Infectious etiologies of rhabdomyolysis: three case reports and review. Clin Infect Dis. 1996, 22:642-9. 10.1093/clinids/22.4.642
10. Crum-Cianflone NF: Bacterial, fungal, parasitic, and viral myositis. Clin Microbiol Rev. 2008, 21:475-94. 10.1128/CMR.00001-08
11. Huerta-Alardín AL, Varon J, Marik PE: Bench-to-bedside review: rhabdomyolysis -- an overview for clinicians. Crit Care. 2005, 9:158-69. 10.1186/cc2978
12. Runnstrom M, Ebied AM, Khoury AP, Reddy R: Influenza-induced rhabdomyolysis. BMJ Case Rep. 2018, 11:011356/bcr-2018-226601
13. Fadila MF, Wool KJ: Rhabdomyolysis secondary to influenza a infection: a case report and review of the literature. N Am J Med Sci. 2015, 7:122-4. 10.4103/1947-2714.153926
14. Ayala E, Kagawa FT, Wehner JH, Tam I, Upadhyay D: Rhabdomyolysis associated with 2009 influenza A(H1N1). JAMA. 2009, 302:1863-4. 10.1001/jama.2009.1582
15. Tamala T, Takada T, Takagi D, Takeyama N, Kitazawa Y: Acute renal failure due to rhabdomyolysis associated with echovirus 9 infection: a case report and review of literature. Jpn J Med. 1989, 28:237-42. 10.1093/clinmed/192.8.237
16. Jin M, Tong Q: Rhabdomyolysis as potential late complication associated with COVID-19. Emerg Infect Dis. 2020, 26:1816-20. 10.3201/eid2607.200445
17. Suwanmongkol K, Shabarek N: Rhabdomyolysis as a presentation of 2019 novel coronavirus disease. Cureus. 2020, 12:10.7759/cureus.7561
18. Valente-Acosta B, Moreno-Sanches F, Fueyo-Rodriguez O, Palomar-Lever A: Rhabdomyolysis as an initial presentation in a patient diagnosed with COVID-19. BMJ Case Rep. 2020, 13:10.1136/bcr-2020-236719
19. Chan KH, Farouji I, Abu Hanoud A, Slim J: Weakness and elevated creatinine kinase as the initial presentation of coronavirus disease 2019 (COVID-19). Am J Emerg Med. 2020, 38:1-5. 10.1016/j.ajem.2020.05.015
20. Meegada S, Muppidi V, Wilkinson DC 3rd, Siddamreddy S, Katta SK: Coronavirus disease 2019-induced rhabdomyolysis. Cureus. 2020, 12:10.7759/cureus.10123
21. Gefen AM, Palumbo N, Nathan SK, Singer PS, Castellanos-reyes LJ, Sethna CB: Pediatric COVID-19-associated rhabdomyolysis: a case report. Pediatr Nephrol. 2020, 35:1517-20. 10.1007/s00467-020-04617-0
22. Tram N, Chioldini B, Montesinos I, et al.: Rhabdomyolysis and acute kidney injury as leading COVID-19 presentation in an adolescent. Pediatr Infect Dis J. 2020, 39:514-5. 10.1097/INF.0000000000002853
23. McCarthy D: Letters to the Editor. Prog Transplant. 2001, 11:162. 10.7182/prtr.11.3 hh6665126116783
24. Anwar H, Al Lawati A: Adolescent COVID-19-associated fatal rhabdomyolysis. J Prim Care Community Health. 2020, 11:10.1177/2151032720985641
25. Samies NL, Pinninti S, James SH: Rhabdomyolysis and acute renal failure in an adolescent with coronavirus disease 2019. J Pediatric Infect Dis Soc. 2020, 9:507-9. 10.1093/jpids/piaa083
26. Vazquez Lanzasanta M, Zamó A, et al.: Benezac acne viral myositis in African migrants: a clinical, serological, and pathological study. Muscle Nerve. 2019, 60:586-90. 10.1002/mus.26679
27. Wu VC, Hsuheh PR, Lin WC, Huang JW, Tsai HB, Chen YM, Wu KD: Acute renal failure in SARS patients: more than rhabdomyolysis. Nephrol Dial Transplant. 2004, 19:5180-2. 10.1093/ndt/gfh436
28. Chen L, Hsu CW, Tian YC, Fang JT: Rhabdomyolysis associated with acute renal failure in patients with severe acute respiratory syndrome. Int J Clin Pract. 2005, 59:1162-6. 10.1111/j.1742-4221.2005.05040.x